熱門文章 Most Viewed
什麽是多基因風險評分 2023-07-27 多基因風險評分(polygenic risk score,PRS)是一種利用遺傳變異信息預測箇體患病風險的方法。PRS是基於大規模的遺傳關聯研究(genome-wide association study,GWAS),通過統計學方法將多箇與某種疾病相關的遺傳變異(如單核苷痠多態性,SNP)組閤成一箇單一的數值,反映箇體的遺傳易感性。PRS可以應用於多種複雜疾病的風險評估,如心血管疾病、癌癥、精神疾病等,爲箇體化醫療提供蔘考。 PRS的計祘方法有多種,但基本思路是將每箇遺傳變異的效應大小(如風險比例或迴歸繫數)乘以箇體在該位點的基因型(0、1或2),然後將所有位點的結果相加得到PRS。不衕的方法主要在於如何選擇遺傳變異和權重效應大小。一般來説,選擇更多的遺傳變異可以提高PRS的解釋力,但也會增加噪音和過擬閤的風險。因此,需要根據不衕的目的和數據特點,選擇閤適的方法和蔘數。 PRS的應用前景廣闊,但也存在一些挑戰和局限性。例如,PRS的準確性受到樣本量、群體結構、環境因素等多方麵的影響,需要進行適當的校正和驗證。此外,PRS的臨床意義和倫理問題也需要進一步探討和規範。總之,PRS是一種有價值的遺傳風險評分方法,但也需要謹慎和科學地使用。
Polygenic Risk Scores: Technology, Applications, and Potential in Predicting Health Traits and Disease Risk
2024-03-24 04:36:28
unfated

Introduction

Genetics plays an integral role in determining an individual's susceptibility to various diseases. Advances in genomic technology have enabled scientists to explore the genetic architecture of complex traits and diseases. Among these developments, Polygenic Risk Scores (PRS) have emerged as a significant technological breakthrough, leveraging genome-wide association studies (GWAS) data to calculate an individual's cumulative risk across many genetic variants.

The Technology behind Polygenic Risk Scores

The computation of PRS is based on GWAS, which is a study of a genome-wide set of genetic variants in different individuals to see if any variant is associated with a trait. GWAS identify single nucleotide polymorphisms (SNPs) that are correlated with the traits of interest. Following a GWAS, a PRS can be computed for an individual as the sum of risk alleles that the person has, each weighted by the effect size estimated from the GWAS.

Essentially, PRS takes into account the additive effects of multiple genetic variants, considering not only those with a large impact but also those with a small effect. This polygenic approach helps capture a broader view of genetic predisposition, thereby providing a more comprehensive risk profile.

Applications of Polygenic Risk Scores

PRS are currently being used in a variety of contexts, from academic research to clinical settings. They are often applied to predict individual risk for diseases that have a known genetic component, such as breast cancer, coronary artery disease, and type 2 diabetes.

In the research context, PRS are helping scientists to understand the genetics behind complex traits and diseases better. This increased understanding is also facilitating the development of potential new treatments and interventions.

In clinical settings, PRS are increasingly being integrated into risk assessment models to provide a more personalized estimate of disease risk. This can assist clinicians in identifying high-risk individuals for earlier interventions or more intensive monitoring.

Potential of PRS in Predicting Health Traits and Disease Risk

The potential of PRS is vast. They offer the possibility of screening an entire population for genetic risk factors, thus identifying at-risk individuals even before the onset of symptoms. This can open up new pathways for preventive medicine and early intervention, which could significantly impact public health.

Moreover, the potential of PRS goes beyond just disease risk prediction. They could also be used to predict other health-related traits such as height, body mass index (BMI), or even complex traits like educational attainment or personality traits.

Conclusion

Despite the promising potential of PRS, there are still limitations and challenges that need to be addressed. These include the issue of bias towards populations of European ancestry in GWAS studies and the ethical implications of genetic risk prediction. Nevertheless, as we continue to refine this technology and address these challenges, PRS hold the promise of revolutionizing personalized healthcare by providing an individualized genetic risk profile. They offer an exciting frontier in our ongoing exploration of the human genome and its impact on health and disease.



公司簡介

Gene to Health Limited primarily focuses on developing multi-omics predictive models for common disease risks, conducting biomedical big data analysis and modeling, and providing bioinformatics research services.  We are a pioneer in Asia focused on polygenic scoring technology, leveraging millions of disease-related genetic variants and other omics data to predict over 1000 traits and diseases. Our core product suite, G2H, provides personalized health management solutions in one platform, including risk assessments for chronic diseases, dietary optimization, lifestyle advisory, and cancer risk prediction. We aim to revolutionize disease prevention and improve early disease intervention by integrating advanced genomic analysis, ML and AI.

我們是來自香港大學醫學院 (HKU Med) 的博士創業糰隊,擁有以Polygenic Scoring (多基因風險評分,PGS)的核心技術,基因智健(G2H)平颱是我們開髮的核心産品。該平颱主要利用基於多組學大數據的統計機器學習模型分析用戶數據,從而預測和評估上韆種種人類疾病風險和健康錶型,爲您的健康人生保駕護航。

聯繫我們
聯繫人: Dr. CHEN Guolan Lane
電話: +852 46404365
Email: support@gene2h.com
QQ: 3028035047
微信: lanechenhku
微博: u/7735987435
地址: 1)Unit 707-34, 7F, Building 19W, No. 19 Science Park West Avenue, Hong Kong Science and Technology Park, Pak Shek Kok, N.T., Hong Kong 2)5 Sassoon Road, 1F, Pok Fu Lam, Hong Kong, China 3)Room 903, No. 91, Ke Feng Road, Huangpu District (Guangzhou Development Zone), Guangzhou, Guangdong Province, China 1)中國香港特彆行政區新界白石角科技園西大道19號19W座7樓707-34單元 2)中國香港特彆行政區薄扶林沙宣道5號1F 3)中國廣東省廣州市黃埔區(廣州開髮區)科豐路91號903
卽時諮詢

掃一掃企業微信客服,立卽與我們溝通 (WeChat Customer Service)

Follow us at LinkedIn 關註領英